Study: Aygun 2024, The Lancet Haematology

Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial

Citation

Aygun B, Lane A, Smart LR et al (2024). The Lancet Haematology. PubMed id 38701812.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Sickle cell disease: what it is, treatment and newborn screening Tier B thin

    B 606 children aged 1 to 10 with haemoglobin SS or S-beta-zero thalassaemia given hydroxyurea in Kenya, Uganda, Angola and the Democratic Republic of Congo (635 enrolled) (n=606)

    Open-label, non-randomised phase 1/2 trial (REACH) with up to 8 years of follow-up.

    Escalating hydroxyurea under monitoring to the maximum tolerated dose reduced pain episodes (rate ratio 0.60 against the fixed-dose phase), acute chest syndrome (0.21), malaria (0.58) and non-malarial infections (0.52), and raised haemoglobin from 7.3 to 8.5 g/dL; serious side effects were uncommon. The abstract gave no significant change in deaths (0.70, P 0.50).

    As recorded in this card: Aygun B, Lane A, Smart LR et al (2024), The Lancet Haematology, [primary]

    Note: Uncontrolled: it compares dosing phases within the same children, not against placebo. Participants were selected by haemoglobin genotype.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.